Fluoxetine
| Evidence Level: L5 | Predicted Indications: 8 |
Table of Contents
Fluoxetine: Schizoid personality disorder
One-Sentence Summary
Fluoxetine is a serotonin-focused antidepressant. The TxGNN model (deep learning) predicts it may be useful for schizoid personality disorder (score 0.9992), but the data compiled for this report contain no clinical trials and only 2 loosely related publications (one general review, one depression cohort study). This prediction is a computational signal only; the score comes from the TxGNN model and may reflect similarities the model learned between related diseases, not biological evidence.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Schizoid personality disorder |
| TxGNN Prediction Score | 0.9992 |
| Evidence Level | L5 |
| Australia Market Status | Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 1 (valid: 1) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data are not available in the data compiled for this report. Fluoxetine is generally understood to act by inhibiting serotonin reuptake. In theory, serotonin modulation might influence affective blunting or social withdrawal, which are features of schizoid personality disorder.
This reasoning is speculative. Schizoid personality disorder is a long-standing pattern of detachment and restricted emotional expression, which is quite different from the mood and anxiety conditions in which fluoxetine is used. The retrieved literature is a general review of drug treatment for Cluster A personality disorders and a study of depression outcomes. Neither shows that fluoxetine works in schizoid personality disorder. The high score therefore reflects a computational pattern, not demonstrated benefit.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 29955451 | 2016 | Review | The Mental Health Clinician | Reviews drug treatment of Cluster A personality disorders (paranoid, schizoid, schizotypal). It describes isolation, avoidance of relationships and reduced quality of life, and does not show fluoxetine efficacy for schizoid personality disorder. |
| 16390895 | 2006 | Cohort | American Journal of Psychiatry | Follows depressed patients over 6 months of treatment to identify predictors of illness course. It concerns depression, not schizoid personality disorder. |
Australia Market Information
| ARTG Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| ARTG 1434L | FLUOTEX | Capsule 20 mg (as hydrochloride) | Not stated in the licence record |
Safety Considerations
- Drug Interactions: The interaction screen returned 100 recorded interactions, and 20 were available for review. Major-level interactions include bupropion, lorcaserin, diethylpropion, dolasetron, eliglustat, palonosetron and cisapride. Moderate-level examples include acetylsalicylic acid, morphine, clarithromycin, famotidine and loperamide.
- Relations recorded in the knowledge graph (not label text): Contraindication relations are recorded for conditions including epilepsy, bipolar disorder, liver failure and liver disease, diabetes and diabetic ketoacidosis, neutropenia and agranulocytosis, blood coagulation disease, stroke and cerebrovascular disorder, myocardial infarction, orthostatic hypotension, and benign prostatic hyperplasia. These come from a computational graph and should be checked against the approved label.
Please refer to the TGA-approved Product Information (PI) for formal warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests on a model score alone. There are no registered trials and no study showing fluoxetine benefit in schizoid personality disorder, so the evidence level is L5.
To proceed, the following is needed:
- Controlled studies (or at least well-designed open-label studies) of fluoxetine specifically in schizoid personality disorder
- Detailed mechanism of action data and a clear rationale linking it to the core features of the disorder
- Review of the TGA Product Information for warnings and contraindications
- A safety plan for patients with the comorbid conditions listed above and for the major interacting drugs
Among the other predictions generated for fluoxetine, phobic disorder had the strongest support (one completed Phase 3 trial in childhood social phobia). It may be a better candidate for further evaluation.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.